Discover and read the best of Twitter Threads about #ASPHO2021
Most recents (9)
Dr. Sidonio reviewing treatment decisions re: inhibitor patients in the #emicizumab era at #ASPHO2021 - starting with a reminder about bypassing agents and their unique dosing 1/n 
ITI (high dose factor exposure) is the standard for getting rid of inhibitors -- worse success if historical high peak titre, time since dx of inhibitor, etc. 2/n
But despite that it's expensive, burdensome... all the major organizations nationally and internationally say you should attempt it! 3/n
Now for an update on #TTP -- always a disease I enjoy teaching about -- the pathophysiology combines so much #heme goodness. Also, I always enjoy the summary slide up front from Dr. George. #ASPHO2021 1/n
For those studying for boards in the future... this is the classic TTP blood smear! #mededpearls #TTP #ADAMTS13 #ASPHO2021 2/n
Hereditary TTP management summarized here -- nice to have it on one slide! 3/n
Up next - Update on TMA! (thrombotic microangiopathy) at #ASPHO2021 Thread here 1/n
Transplant associated-TMA (TA-TMA) defined here. Look at the labs that you should use to help guide this diagnosis. High risk criteria of TA-TMA on second slide. 2/n
TA-TMA have a really high morbidity with a lot of multiorgan injury (intestinal, pulmonary, CNS)... scary -- I don't see this often (since I am no longer working in transplant patients) but the information can be translatable to other TMA type processes. 3/n
35% of children in the US qualify for coverage with Medicaid/CHIP
70% of #sicklecell patients have Medicaid/CHIP (!!!!!)
We think that brings equality because Medicaid/CHIP brings access to care (but not all physicians accept patients with Medicaid/CHIP).
#ASPHO2021 1/n
70% of #sicklecell patients have Medicaid/CHIP (!!!!!)
We think that brings equality because Medicaid/CHIP brings access to care (but not all physicians accept patients with Medicaid/CHIP).
#ASPHO2021 1/n
Why is this important? Because patients with sickle cell disease have a decrease life expectancy! (by 30 years!) Not only that -- Dr. Allison King found that patients with #sicklecell saw that those on Medicaid clearly repeated grade levels. #ASPHO2021 2/n
From the SIT trial - silent cerebral infarcts wasn’t the risk factor.. per capita income was! Look at the OR of 6.4 for those in the lowest quartile. The most at risk are our older males. #ASPHO2021 3/n
Management of iron overload for #phodocs to pay attention to. Talk by Dr. Lalefar from @UCSFBenioffOAK. Follow this thread 1/n
Who should be monitored for iron overload? Those that have a transfused volume >100 ml/kg (~10 transfusions) #ASPHO2021 2/n
Dr. Lalefar suggests checking ferritin, but remember to check with other iron studies. She says a serum ferritin >1000 ug/L is the common threshold used. (But this was based on correlation studies with liver iron from mostly Caucasian hemochromatosis patients) 3/n
Peak risk of catheter associated DVT at 4 days after catheter insertion. The CRETE trial used ppx enoxaparin on day one (target 0.2-0.5 anti-Xa level) and showed may be able to prevent DVT. 1/n
But amongst infants (child <1 year) no real change in risk - but older children have risk reduction from Dr. Faustino's CRETE trial. He suggests due to differences in size of line versus vein size (infants have less delta) 2/n
Infants have lower thrombin generation which may be why ppx enoxaparin may not help them as much -- they then thought about trying therapeutic enoxaparin in infants to prevent CA-DVT. 3/n
Snapshot of current #phodocs peds data on doac studies. Rivaroxaban (einstein jr) and Dabigatran completed.. data to follow in this thread #ASPHO2021 1/n
Prelim data from rivaroxaban showed <12 kg patients needed TID dosing. The phase 3 dosing is given here. Phase 3 data showed decreased rate of VTE and no major bleeding. 2/n
Dabigatran (DIVERSITY) data was published Jan 2021 phase 2b/3 non-inferiority trial. They used composite primary endpoint of complete resolution, freedom from recurrent VTE and VTE-related death. 3/n
Will tweet some pearls from @Sisk_MD's (young investigator award winner) plenary talk on communication breakdown in #pediatriconcology #phodocs here at #ASPHO2021 1/n
Communication has lots of functions -- not just passing information. @Sisk_MD outlines 8 here. 2/n
He did qualitative research with a total of 80 parents of children with cancer across different time points and different ages. ... 95% of parents experienced negative communication experiences! (with everyone - ALL team members) 3/n
Queuing up Dr. Kwiatkowski's of @CHOP_Research giving updated results of the #HGB-206 lentiglobin gene therapy for #sicklecelldisease in today's plenary session at #ASPHO2021. Follow this thread for more 1/n
Why are we talking about gene therapy for #sicklecell. It's estimated <15% of patients have a sibling matched stem cell transplant donor! 2/n
Today's talk is going over group C - eligibility included here. Enrollment has been completed. This is for SS and S beta0 and S beta+ genotypes. 3/n
